Abstract: In March 2025， the American Association for the Study of Liver Diseases published its latest practice statement on metabolic dysfunction-associated steatotic liver disease （MASLD） in children. Compared with previous guidelines， this statement adopts the latest nomenclature and diagnostic criteria for MASLD， emphasizes hepatic steatosis in the presence of at least one cardiovascular metabolic risk factor， and elaborates on the unique epidemiological characteristics， pathophysiological patterns， and natural history of pediatric MASLD. Based on evidence-based medicine， the statement provides comprehensive guidance on the screening， diagnosis， treatment and monitoring of MASLD in children and emphasizes that lifestyle interventions form the cornerstone of treatment， and at present， there are still no drugs approved for the treatment of MASLD in children. This article gives an excerpt of the key recommendations in the practice statement.